Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...

Aggregate cash and cash equivalents and short-term investments were $412.3M and $186.2M at December 31, 2024 and December 31, 2023, ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...

Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...